Literature DB >> 26818839

Stabilization of Live Attenuated Influenza Vaccines by Freeze Drying, Spray Drying, and Foam Drying.

Phillip M Lovalenti1, Jeff Anderl1, Luisa Yee1, Van Nguyen1, Behnaz Ghavami1, Satoshi Ohtake1, Atul Saxena1, Thomas Voss2, Vu Truong-Le3.   

Abstract

PURPOSE: The goal of this research is to develop stable formulations for live attenuated influenza vaccines (LAIV) by employing the drying methods freeze drying, spray drying, and foam drying.
METHODS: Formulated live attenuated Type-A H1N1 and B-strain influenza vaccines with a variety of excipient combinations were dried using one of the three drying methods. Process and storage stability at 4, 25 and 37°C of the LAIV in these formulations was monitored using a TCID50 potency assay. Their immunogenicity was also evaluated in a ferret model.
RESULTS: The thermal stability of H1N1 vaccine was significantly enhanced through application of unique formulation combinations and drying processes. Foam dried formulations were as much as an order of magnitude more stable than either spray dried or freeze dried formulations, while exhibiting low process loss and full retention of immunogenicity. Based on long-term stability data, foam dried formulations exhibited a shelf life at 4, 25 and 37°C of >2, 1.5 years and 4.5 months, respectively. Foam dried LAIV Type-B manufactured using the same formulation and process parameters as H1N1 were imparted with a similar level of stability.
CONCLUSION: Foam drying processing methods with appropriate selection of formulation components can produce an order of magnitude improvement in LAIV stability over other drying methods.

Entities:  

Keywords:  Attenuated; Drying; Influenza; Stability; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 26818839     DOI: 10.1007/s11095-016-1860-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation.

Authors:  Yuh-Fun Maa; Mahmoud Ameri; Cassandra Shu; Lendon G Payne; Dexiang Chen
Journal:  J Pharm Sci       Date:  2004-07       Impact factor: 3.534

Review 2.  The challenge of drying method selection for protein pharmaceuticals: product quality implications.

Authors:  Ahmad M Abdul-Fattah; Devendra S Kalonia; Michael J Pikal
Journal:  J Pharm Sci       Date:  2007-08       Impact factor: 3.534

3.  Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on Stability II: stability of a vaccine.

Authors:  Ahmad M Abdul-Fattah; Vu Truong-Le; Luisa Yee; Emilie Pan; Yi Ao; Devendra S Kalonia; Michael J Pikal
Journal:  Pharm Res       Date:  2007-02-15       Impact factor: 4.200

4.  Stabilizing cold-adapted influenza virus vaccine under various storage conditions.

Authors:  Dean A Yannarell; Kenneth M Goldberg; Richard N Hjorth
Journal:  J Virol Methods       Date:  2002-04       Impact factor: 2.014

Review 5.  Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies.

Authors:  Ozan S Kumru; Sangeeta B Joshi; Dawn E Smith; C Russell Middaugh; Ted Prusik; David B Volkin
Journal:  Biologicals       Date:  2014-07-01       Impact factor: 1.856

6.  Heat-stable measles vaccine produced by spray drying.

Authors:  Satoshi Ohtake; Russell A Martin; Luisa Yee; Dexiang Chen; Debra D Kristensen; David Lechuga-Ballesteros; Vu Truong-Le
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

7.  Drying-induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): stability of a monoclonal antibody.

Authors:  Ahmad M Abdul-Fattah; Vu Truong-Le; Luisa Yee; Lauren Nguyen; Devendra S Kalonia; Marcus T Cicerone; Michael J Pikal
Journal:  J Pharm Sci       Date:  2007-08       Impact factor: 3.534

Review 8.  Development of stable influenza vaccine powder formulations: challenges and possibilities.

Authors:  J-P Amorij; A Huckriede; J Wilschut; H W Frijlink; W L J Hinrichs
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

  8 in total
  14 in total

1.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

Review 2.  A guide to oral vaccination: Highlighting electrospraying as a promising manufacturing technique toward a successful oral vaccine development.

Authors:  Ahmad M Aldossary; Chinedu S M Ekweremadu; Ifunanya M Offe; Haya A Alfassam; Sooyeon Han; Vivian C Onyali; Chukwuebuka H Ozoude; Emmanuel A Ayeni; Chinekwu S Nwagwu; Abdulrahman A Halwani; Nada H Almozain; Essam A Tawfik
Journal:  Saudi Pharm J       Date:  2022-03-15       Impact factor: 4.562

Review 3.  Developments in the formulation and delivery of spray dried vaccines.

Authors:  Gaurav Kanojia; Rimko Ten Have; Peter C Soema; Henderik Frijlink; Jean-Pierre Amorij; Gideon Kersten
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

4.  Thermal Stabilization of Viral Vaccines in Low-Cost Sugar Films.

Authors:  Vincent Leung; Jonathan Mapletoft; Ali Zhang; Amanda Lee; Fatemeh Vahedi; Marianne Chew; Alexandra Szewczyk; Sana Jahanshahi-Anbuhi; Jann Ang; Braeden Cowbrough; Matthew S Miller; Ali Ashkar; Carlos D M Filipe
Journal:  Sci Rep       Date:  2019-05-21       Impact factor: 4.379

5.  Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge.

Authors:  Jasmine Tomar; Harshad P Patil; Gustavo Bracho; Wouter F Tonnis; Henderik W Frijlink; Nikolai Petrovsky; Rita Vanbever; Anke Huckriede; Wouter L J Hinrichs
Journal:  J Control Release       Date:  2018-09-12       Impact factor: 9.776

6.  Evaluation of Microwave Vacuum Drying as an Alternative to Freeze-Drying of Biologics and Vaccines: the Power of Simple Modeling to Identify a Mechanism for Faster Drying Times Achieved with Microwave.

Authors:  Akhilesh Bhambhani; Justin Stanbro; Daniel Roth; Elizabeth Sullivan; Morrisa Jones; Robert Evans; Jeffrey Blue
Journal:  AAPS PharmSciTech       Date:  2021-01-19       Impact factor: 3.246

Review 7.  Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines.

Authors:  Lantian Lu; Viet Tram Duong; Ahmed O Shalash; Mariusz Skwarczynski; Istvan Toth
Journal:  Vaccines (Basel)       Date:  2021-05-28

8.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

9.  Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus.

Authors:  Yoshita Bhide; Jasmine Tomar; Wei Dong; Jacqueline de Vries-Idema; Henderik W Frijlink; Anke Huckriede; Wouter L J Hinrichs
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

10.  Pulmonary immunization: deposition site is of minor relevance for influenza vaccination but deep lung deposition is crucial for hepatitis B vaccination.

Authors:  Jasmine Tomar; Wouter F Tonnis; Harshad P Patil; Anne H de Boer; Paul Hagedoorn; Rita Vanbever; Henderik W Frijlink; Wouter L J Hinrichs
Journal:  Acta Pharm Sin B       Date:  2019-05-28       Impact factor: 11.413

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.